The Anti-Rheumatic Drugs market in Netherlands has been experiencing steady growth in recent years.
Customer preferences: Patients in Netherlands suffering from rheumatoid arthritis and other rheumatic diseases have been increasingly opting for biologic drugs, which are more expensive but offer better efficacy and fewer side effects compared to traditional disease-modifying antirheumatic drugs (DMARDs). This trend is in line with the global market, where biologics are gaining popularity due to their targeted mechanism of action and ability to modify the disease course.
Trends in the market: The Dutch government has been implementing cost-containment measures to reduce the expenditure on healthcare, including the reimbursement of expensive biologics. This has led to a shift towards biosimilars, which are cheaper versions of biologic drugs. The introduction of biosimilars has increased competition in the market, resulting in lower prices for both originator biologics and biosimilars. This trend is expected to continue, as more biologics are set to lose their patent protection in the coming years.
Local special circumstances: The Netherlands has a well-established healthcare system, with universal coverage and a strong emphasis on preventive care. The country has a high prevalence of rheumatic diseases, with an estimated 2.4 million people suffering from arthritis. The aging population and increasing prevalence of obesity are expected to further drive the demand for anti-rheumatic drugs in the coming years.
Underlying macroeconomic factors: The Dutch economy has been growing steadily, with a GDP growth rate of 1.8% in 2019. The country has a highly skilled workforce and a favorable business climate, making it an attractive destination for foreign investment. The pharmaceutical industry is a key contributor to the Dutch economy, with several multinational companies having a presence in the country. The government has been investing in research and development to promote innovation in the healthcare sector. In conclusion, the Anti-Rheumatic Drugs market in Netherlands is expected to continue its growth trajectory, driven by increasing demand for biologics, the shift towards biosimilars, and the favorable macroeconomic environment. However, cost-containment measures and increasing competition may pose challenges for market players in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
